<DOC>
	<DOCNO>NCT02170311</DOCNO>
	<brief_summary>The safety , tolerability , pharmacokinetics pharmacodynamics Z-213 investigate patient iron-deficiency anemia administration single dose ( 100 mg , 500 mg , 800 mg 1,000 mg iron ) .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics Safety Study Z-213 Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Patients mild iron deficiency anemia Patients anemia cause condition iron deficiency Patients abnormal laboratory test value screen Creactive protein , Serum phosphorus , Aspartate aminotransferase , Alanine aminotransferase , Total bilirubin Patients liver , kidney circulatory system disease Patients history present illness malignant tumor autoimmune disease Patients underwent intravenous administration iron preparation , administration erythropoiesis stimulation agent blood transfusion within 8 week screen Patients underwent oral administration iron preparation ( include overthecounter drug supplement ) within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Z-213 , Ferric carboxymaltose , Iron , Iron-deficiency-anemia</keyword>
</DOC>